Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Postcovid cognitive decline, its risk factors and diagnostic biomarkers
https://doi.org/10.33667/2078-5631-2025-15-26-30
Abstract
Cognitive impairment (CI) is one of the main symptoms of both the acute period of COVID-19 and post-COVID syndrome, manifested by memory, attention and executive functions decline, which may persist or worsen months after infection. Risk factors for developing postcovid CI (PCI) include old age, female gender, low educational and socio-economic status, prolonged social isolation, severe COVID-19, use of certain medications, and concomitant diseases such as dementia and cardiovascular diseases. Vaccination against COVID-19 is considered as an effective way to prevent PCI. Diagnosis of PCI is based on the study of biomarkers in blood and cerebrospinal fluid (CSF), neuroimaging and neurophysiological data. Studies have revealed a link between cognitive impairment and the presence of antineuronal antibodies in the blood and CSF, structural changes in the brain (decrease in gray matter thickness and tissue damage in memory and attention areas), decreased glucose metabolism in key areas of the brain (according to PET scans) and abnormalities in brain electrical activity (according to EEG data). PCI is a serious problem for global health, exacerbated by the COVID-19 pandemic, which requires a comprehensive approach to the study, diagnosis, treatment and rehabilitation of patients.
About the Authors
А. G. Mikheeva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Mikheeva Anna G., postgraduate student at Dept of Neurology with the Clinic, Medical Education Institute
T. M. Alekseeva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Alekseeva Tatyana M., DM Sci (habil.), head of Dept of Neurology with the Clinic, Medical Education Institute
References
1. Soriano J. B., Murthy S., Marshall J. C. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22 (4): e102–e107. DOI: 10.1016/S 1473-3099 (21) 00703-9
2. Alkodaymi M. S., Omrani O. A., Fawzy N. A. et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022; 28 (5): 657–666. DOI: 10.1016/j.cmi.2022.01.014
3. Monje M., Iwasaki A. The neurobiology of long COVID. Neuron. 2022; 110 (21): 3484–3496. DOI: 10.1016/j.neuron.2022.10.006
4. Михеева А. Г., Топузова М. П., Михеева М. Г., Алексеева Т. М., Каронова Т. Л. Эмоциональные нарушения в структуре постковидного синдрома. Медицинский совет. 2024; 18 (5): 108–116. DOI: 10.21518/ms2024-148
5. Mikheeva A. G., Topuzova M. P., Mikheeva M. G., Alekseeva T. M., Karonova T. L. Emotional disturbances in postcovid syndrome structure. Meditsinskiy Sovet. 2024; 18 (5): 108–116. DOI: 10.21518/ms2024-148.
6. Ceban F., Ling S., Lui L. M.W. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022; 101: 93–135. DOI: 10.1016/j.bbi.2021.12.020
7. Matias-Guiu J.A., Herrera E., González-Nosti M. et al. Development of criteria for cognitive dysfunction in post-COVID syndrome: the IC–CoDi-COVID approach. Psychiatry Res. 2023; 319: 115006. DOI: 10.1016/j.psychres.2022.115006
8. Amalakanti S., Arepalli K. V.R., Jillella J. P. Cognitive assessment in asymptomatic COVID-19 subjects. Virusdisease. 2021; 32 (1): 146–149. DOI: 10.1007/s13337-021-00663-w
9. Tolentino J. C., Gjorup A. L.T., Schmidt G. J., Schmidt SL. Early attention impairment in a patient with COVID-19. Psychiatry Clin Neurosci. 2021; 75 (2): 66–67. DOI: 10.1111/pcn.13178
10. Beaud V., Crottaz-Herbette S., Dunet V. et al. Pattern of cognitive deficits in severe COVID-19. J Neurol Neurosurg Psychiatry. 2021; 92 (5): 567–568. DOI: 10.1136/jnnp-2020325173
11. Groiss S. J., Balloff C., Elben S. et al. Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19-A Case Series. Front Neurol. 2020; 11: 574004. DOI: 10.3389/fneur.2020.574004
12. Hellmuth J., Barnett T. A., Asken B. M. et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol. 2021; 27 (1): 191–195. DOI: 10.1007/ s13365-021-00954-4
13. Negrini F., Ferrario I., Mazziotti D. et al. Neuropsychological Features of Severe Hospitalized Coronavirus Disease 2019 Patients at Clinical Stability and Clues for Postacute Rehabilitation. Arch Phys Med Rehabil. 2021; 102 (1): 155–158. DOI: 10.1016/j.apmr.2020.09.376
14. Whiteside D. M., Oleynick V., Holker E. et al. Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model. Clin Neuropsychol. 2021; 35 (4): 799–818. DOI: 10.1080/13854046.2021.1874056
15. Ermis U., Rust M. I., Bungenberg J. et al. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurol Res Pract. 2021; 3 (1): 17. DOI: 10.1186/s42466-021-00116-1
16. Alemanno F., Houdayer E., Parma A. et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS One. 2021; 16 (2): e0246590. DOI: 10.1371/journal.pone.0246590
17. Hosp J. A., Dressing A., Blazhenets G. et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021; 144 (4): 1263–1276. DOI: 10.1093/brain/awab009
18. Méndez R., Balanzá-Martínez V., Luperdi S. C. et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021; 290 (3): 621–631. DOI: 10.1111/ joim.13262
19. Miskowiak K. W., Johnsen S., Sattler S. M. et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021; 46: 39–48. DOI: 10.1016/j.euroneuro.2021.03.019
20. Becker J. H., Lin J. J., Doernberg M. et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021; 4 (10): e2130645. DOI: 10.1001/jamanetworkopen.2021.30645
21. Ariza M., Cano N., Segura B. et al. Neuropsychological impairment in post-COVID condition individuals with and without cognitive complaints. Front Aging Neurosci. 2022; 14: 1029842. DOI: 10.3389/fnagi.2022.1029842
22. Daroische R., Hemminghyth M. S., Eilertsen T. H. et al. Cognitive Impairment After COVID-19-A Review on Objective Test Data. Front Neurol. 2021; 12: 699582. DOI: 10.3389/ fneur.2021.699582
23. Hartung T. J., Neumann C., Bahmer T. et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine. 2022; 53: 101651. DOI: 10.1016/j.eclinm.2022.101651
24. Baseler H. A., Aksoy M., Salawu A. et al. The negative impact of COVID-19 on working memory revealed using a rapid online quiz. PLoS One. 2022; 17 (11): e0269353. DOI:10.1371/ journal.pone.0269353
25. PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022; 10 (8): 761–775. DOI: 10.1016/S 2213-2600 (22) 00127-8
26. Asadi-Pooya A.A., Akbari A., Emami A. et al. Long COVID syndrome-associated brain fog. J Med Virol. 2022; 94 (3): 979–984. DOI: 10.1002/jmv.27404
27. Ortona E., Malorni W. Long COVID: to investigate immunological mechanisms and sex/ gender related aspects as fundamental steps for tailored therapy. Eur Respir J. 2022; 59 (2): 2102245. DOI: 10.1183/13993003.02245-2021
28. Osmanov I. M., Spiridonova E., Bobkova P. et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J. 2022; 59 (2): 2101341. DOI: 10.1183/13993003.01341-2021
29. Liu Y. H., Wang Y. R., Wang Q. H. et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener. 2021; 16 (1): 48. DOI: 10.1186/ s13024-021-00469-w
30. Politi J., Martín-Sánchez M., Mercuriali L. et al. Epidemiological characteristics and outcomes of COVID-19 cases: mortality inequalities by socio-economic status, Barcelona, Spain, 24 February to 4 May 2020. Euro Surveill. 2021; 26 (20): 2001138. DOI: 10.2807/15607917.ES.2021.26.20.2001138
31. Manca R., De Marco M., Venneri A. The Impact of COVID-19 Infection and Enforced Prolonged Social Isolation on Neuropsychiatric Symptoms in Older Adults With and Without Dementia: A Review. Front Psychiatry. 2020; 11: 585540. DOI: 10.3389/ fpsyt.2020.585540
32. Bethell J., Aelick K., Babineau J. et al. Social Connection in Long-Term Care Homes: A Scoping Review of Published Research on the Mental Health Impacts and Potential Strategies During COVID-19. J Am Med Dir Assoc. 2021; 22 (2): 228–237.e25. DOI: 10.1016/j. jamda.2020.11.025
33. Simonetti A., Pais C., Jones M. et al. Neuropsychiatric Symptoms in Elderly With Dementia During COVID-19 Pandemic: Definition, Treatment, and Future Directions. Front Psychiatry. 2020; 11: 579842. DOI: 10.3389/fpsyt.2020.579842
34. Chen Z. C., Liu S., Gan J. et al. The Impact of the COVID-19 Pandemic and Lockdown on Mild Cognitive Impairment, Alzheimer's Disease and Dementia With Lewy Bodies in China: A 1-Year Follow-Up Study. Front Psychiatry. 2021; 12: 711658. DOI: 10.3389/fpsyt.2021.711658
35. Yazdanpanah N., Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022; 94 (1): 54–62. DOI: 10.1002/jmv.27292
36. Mendonça Filho V. C.M., de Oliveira A. G., Maia I. F.V.C. et al. COVID-19 in the nervous system: physiopathology and neurological manifestations. Arq Neuropsiquiatr. 2023; 81 (8): 756–763. DOI: 10.1055/s-0043-1769123
37. Kumar A., Chattopadhyay A., Gupta S. Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications. Asian J Psychiatr. 2022; 73: 103101. DOI: 10.1016/j. ajp.2022.103101
38. Kotfis K., van Diem-Zaal I., Williams Roberson S. et al. The future of intensive care: delirium should no longer be an issue. Crit Care. 2022; 26 (1): 200. DOI: 10.1186/s13054-022-04077-y
39. Neelamegam M., Zgibor J., Chen H. et al. The effect of opioids on the cognitive function of older adults: results from the Personality and Total Health through life study. Age Ageing. 2021; 50 (5): 1699–1708. DOI: 10.1093/ageing/afab048
40. Izcovich A., Siemieniuk R. A., Bartoszko J. J. et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022; 12 (3): e048502. DOI: 10.1136/ bmjopen-2020–048502
41. Borah P., Deb P. K., Chandrasekaran B. et al. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. Front Mol Biosci. 2021; 8: 627723. DOI: 10.3389/fmolb.2021.627723
42. Levaillant M., Wathelet M., Lamer A. et al. Impact of COVID-19 pandemic and lockdowns on the consumption of anxiolytics, hypnotics and antidepressants according to age groups: a French nationwide study. Psychol Med. 2023; 53 (7): 2861–2867. DOI: 10.1017/S 0033291721004839
43. Zhou J., Liu C., Sun Y. et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021; 91: 383–392. DOI: 10.1016/j.bbi.2020.10.019
44. Godeau D., Petit A., Richard I. et al. Return-to-work, disabilities and occupational health in the age of COVID-19. Scand J Work Environ Health. 2021; 47 (5): 408–409. DOI: 10.5271/sjweh.3960
45. Rogers J. P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7 (7): 611–627. DOI: 10.1016/S 2215-0366 (20) 30203-0
46. Vindegaard N., Benros M. E. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020; 89: 531–542. DOI: 10.1016/j.bbi.2020.05.048
47. Ward C. F., Figiel G. S., McDonald W. M. Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Elderly. Am J Geriatr Psychiatry. 2020; 28 (8): 808–811. DOI: 10.1016/j.jagp.2020.05.013
48. Pandharipande P. P., Girard T. D., Jackson J. C. et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013; 369 (14): 1306–16. DOI: 10.1056/NEJMoa1301372
49. Gao P., Liu J., Liu M. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022; 19 (19): 12422. DOI: 10.3390/ijerph191912422
50. Marshall M. The four most urgent questions about long COVID. Nature. 2021; 594 (7862): 168–170. DOI: 10.1038/d41586-021-01511-z
51. Franke C., Boesl F., Goereci Y. et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav Immun. 2023; 109: 139–143. DOI: 10.1016/j.bbi.2023.01.006
52. Apple A. C., Oddi A., Peluso M. J. et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol. 2022; 9 (2): 221–226. DOI: 10.1002/acn3.51498
53. Douaud G., Lee S., Alfaro-Almagro F. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022; 604 (7907): 697–707. DOI: 10.1038/s41586-022-04569-5
54. Cecchetti G., Agosta F., Canu E. et al. Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol. 2022; 269 (7): 3400–3412. DOI: 10.1007/s00415-022-11047-5
55. Rothstein T. L. Cortical Grey matter volume depletion links to neurological sequelae in post COVID-19 «long haulers». BMC Neurol. 2023; 23 (1): 22. DOI: 10.1186/s12883-023-03049-1
56. Miskowiak K. W., Bech J. L., Henriksen A. C. et al. Cerebral Metabolic Rate of Glucose and Cognitive Tests in Long COVID Patients. Brain Sci. 2022; 13 (1): 23. DOI: 10.3390/ brainsci13010023
57. Furlanis G., Buoite Stella A., Biaduzzini F. et al. Cognitive deficit in post-acute COVID-19: an opportunity for EEG evaluation? Neurol Sci. 2023; 44 (5): 1491–1498. DOI: 10.1007/s10072-023-06615-0
58. Damiano R. F., Guedes B. F., de Rocca C. C. et al. Cognitive decline following acute viral infections: literature review and projections for post-COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022; 272 (1): 139–154. DOI: 10.1007/s00406-021-01286-4
Review
For citations:
Mikheeva А.G., Alekseeva T.M. Postcovid cognitive decline, its risk factors and diagnostic biomarkers. Medical alphabet. 2025;(15):26-30. (In Russ.) https://doi.org/10.33667/2078-5631-2025-15-26-30
Views:
22
Email this article 